2026 Alan Melcher: Immunology Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Immunology	76	1928	1764	172	165	342	18511
Medicine	76	18882	17740	1706	1634	454	18679

Overview

Alan Melcher is affiliated with the Institute of Cancer Research in the United Kingdom. Their research spans multiple areas within medicine, biochemistry, genetics, molecular biology, and immunology, with a particular focus on oncology, immunology, genetics, molecular biology, and infectious diseases.

Their main research topics include:

Virus-based gene therapy research
Cancer Immunotherapy and Biomarkers
Immunotherapy and Immune Responses
CAR-T cell therapy research
Interferon and immune responses
Immune Cell Function and Interaction
Cancer Research and Treatments

Alan Melcher has frequently published in several venues, predominantly:

bioRxiv (Cold Spring Harbor Laboratory)
Journal for ImmunoTherapy of Cancer
Nature Communications
Cancer Research
Frontiers in Immunology

Recent publications by Alan Melcher include:

"Oncolytic virotherapy as immunotherapy", 2021, Science
"Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice", 2022, Science Translational Medicine
"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death", 2020, Journal for ImmunoTherapy of Cancer
"Inflammatory microenvironment remodelling by tumour cells after radiotherapy", 2020, Nature reviews. Cancer
"STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy", 2020, Nature Cell Biology

Their collaborative work involves frequent co-authors such as Kevin J. Harrington, Malin Pedersen, Richard G. Vile, Emmanuel C. Patin, and Joan Kyula, indicating active involvement in multi-author scientific studies.

Best Publications

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

Lorenzo Galluzzi;Ilio Vitale;Sarah Warren;Sandy Adjemian

1009
Citations
Inflammatory microenvironment remodelling by tumour cells after radiotherapy.

Martin McLaughlin;Emmanuel C. Patin;Malin Pedersen;Anna Wilkins

857
Citations
Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression

Alan Melcher;Stephen Todryk;Nicola Hardwick;Martin Ford

578
Citations
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Frederick Arce Vargas;Andrew J S Furness;Kevin Litchfield;Kroopa Joshi

575
Citations
Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake.

Stephen Todryk;Alan A. Melcher;Alan A. Melcher;Nicola Hardwick;Emmanouela Linardakis

466
Citations
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade

Adel Samson;Karen J. Scott;David Taggart;Emma J. West

387
Citations
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.

Laura Vidal;Hardev S. Pandha;Timothy A. Yap;Christine L. White

324
Citations
Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide

Alan Melcher;Kelley Parato;Cliona M Rooney;John C Bell

309
Citations
The Case of Oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon

Robin J. Prestwich;Fiona Errington;Rosa M. Diaz;Hardev S. Pandha

262
Citations
Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication

Robin J. Prestwich;Elizabeth J. Ilett;Fiona Errington;Rosa M. Diaz

257
Citations
Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity

Fiona Errington;Lynette Steele;Robin Prestwich;Kevin J. Harrington

250
Citations
Oncolytic viruses: a novel form of immunotherapy

Robin J.D. Prestwich;Kevin J. Harrington;Hardev S. Pandha;Richard G. Vile

236
Citations
Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity

Robin J. Prestwich;Fiona Errington;Elizabeth J. Ilett;Ruth S.M. Morgan

235
Citations
Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8 + T cell trafficking

David Taggart;David Taggart;Tereza Andreou;Karen J Scott;Jennifer Williams

226
Citations
Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer Therapy

Candice Willmon;Kevin Harrington;Timothy Kottke;Robin Prestwich

221
Citations
Measles virus causes immunogenic cell death in human melanoma

Oliver G Donnelly;Fiona Errington-Mais;Lynette Steele;Elizabeth Hadac

221
Citations
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.

Robert A. Adair;Victoria Roulstone;Karen J. Scott;Ruth Morgan

210
Citations
Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus

Jian Qiao;Hongxun Wang;Timothy Kottke;Christine White

208
Citations
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.

C L White;K R Twigger;L Vidal;L Vidal;J S De Bono

206
Citations
ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment

Magnus T. Dillon;Katharina F. Bergerhoff;Malin Pedersen;Harriet Whittock

206
Citations
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies

Eleni Karapanagiotou;Victoria Roulstone;Katie Twigger;Mercel Ball

194
Citations

Frequent Co-Authors

Richard G. Vile Mayo Clinic

Kevin J. Harrington Royal Marsden NHS Foundation Trust

Peter Selby University of Leeds

Timothy Kottke Mayo Clinic

Matthew C. Coffey Oncolytics Biotech (Canada)

Christopher M. Nutting Royal Marsden NHS Foundation Trust

Michael J. Gough Providence Portland Medical Center

Gerard J. Nuovo The Ohio State University

Stephen Todryk Northumbria University

Atique U. Ahmed Northwestern University

External Links

Personal website of Alan Melcher

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

For those interested in advancing their career in healthcare alongside or after studying Immunology, exploring nursing pathways can be valuable. Many students consider programs like Licensed Practical Nurse (LPN), which serve as foundational steps into clinical practice. If convenience and admission ease are priorities, researching which LPN programs are easiest to get into can help identify accessible options.

For more specialized roles, becoming a Nurse Practitioner (NP) is a popular choice. There are many online options designed to simplify the transition with flexible curriculums. Identifying the easiest nurse practitioner program to enroll in may be beneficial for those seeking an efficient path to advanced practice.

If your focus is mental health within immunology-related fields, Psychiatric Mental Health Nurse Practitioner (PMHNP) programs are worth exploring. Discovering the top PMHNP programs ensures quality training and strong clinical placement opportunities. Balancing quality and cost, you might also want to consider the affordable PMHNP programs that make education more financially accessible without compromising standards.

Choosing the right degree path depends on your career goals, budget, and the level of patient care you wish to provide. These nursing pathways complement immunology knowledge, opening doors to impactful healthcare roles nationwide.